STAT’s Adam Feuerstein said via Twitter: “$SAVA – More evidence provided by the company this morning showing futility of simufilam as a treatment for Alzheimer’s disease. Disregard misleading headline, the drug didn’t slow cognitive decline compared to placebo in randomized, withdrawal study.” Shares of Cassava Sciences are down 12% to $22.30 in midday trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAVA:
- Cassava Sciences Plunges despite Solid Drug Study
- Cassava says oral simufilam slowed cognitive decline in withdrawal trial
- Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
- New Research Shows Simufilam Suppresses Overactive mTOR
- Cassava Sciences announces publication on effects of simufilam